tradmap

IDXX Idexx Laboratories

$561.89 +2.91%

Nasdaq 100 CompaniesS&P 500 Companies

Held by SPYVOOIVVQQQQQQM

Healthcare · In Vitro & In Vivo Diagnostic Substances

Idexx Laboratories (IDXX) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $44.3 billion. Shares last traded at $561.89, 26.9% below their 52-week high. Over the past year the stock is up 7.5%. IDXX trades at a price-to-earnings ratio of 41.84, above the In Vitro & In Vivo Diagnostic Substances median of 35.40. Net profit margin is 24.6%, above the peer median of -3.8%. Revenue grew 10.4% year over year.

Market Cap
$44.3B
Shares Out
78.9M
EPS (TTM)
$23.01
P/E Ratio
24.42
P/S Ratio
10.30
P/B Ratio
28.48
Dividend / Share
Dividend Yield
52-Week High
$769.08
52-Week Low
$506.91
Volume
37,912
Avg Vol (3m)
32,988.27

Performance

1W
-2.92%
1M
+6.27%
3M
-4.36%
6M
-20.20%
YTD
-16.18%
1Y
+7.51%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.35
SMA (50)
$562.82
SMA (200)
$633.40
Price vs SMA50
-0.17%
Price vs SMA200
-11.29%
ATR (14)
$17.37

Financials

Revenue
$4.3B
Net Income
$1.1B
Gross Margin
61.8%
Operating Margin
31.6%
Net Margin
24.6%
Return on Equity
68.1%
Return on Assets
31.3%
Current Ratio
1.12
Debt / Equity
0.19
Revenue Growth (YoY)
+10.4%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $3.47 2026-05-05
FY 2025 $13.08 2026-02-20
Q3 2025 $9.99 2025-11-03
Q2 2025 $6.59 2025-08-04
Q1 2026 $2.96 2026-05-05
FY 2025 $10.67 2026-02-20

Full earnings history →

In Vitro & In Vivo Diagnostic Substances peers

IDXX vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap.

P/E vs peers
41.84 / 35.40 med
+18% premium
P/S vs peers
10.30 / 4.39 med
+135% premium
Net margin vs peers
24.6% / -3.8% med
above median
1–14 of 14
IDXXIdexx Laboratories$44.3B41.8410.3024.6%+2.91%
LNTHLantheus Holdings, Inc.$6.8B28.974.3915.2%+0.67%
CLDXCelldex Therapeutics, Inc.$2.5B-9.84-1.47%
NTLAIntellia Therapeutics, Inc.$2.2B-5.30+2.25%
NEOGNeogen Corp$2.0B-1.85+4.14%
QDELQuidelortho Corp$932M+4.27%
ACHVAchieve Life Sciences, Inc.$496M-9.07-9.72%
MYGNMyriad Genetics Inc$429M-1.170.52-44.4%+3.65%
TKNOAlpha Teknova, Inc.$282M-16.326.95-42.6%+6.38%
IMDXInsight Molecular Diagnostics Inc.$176M-3510.5043.48-1.2%+2.25%
ICCCIMMUCELL CORP /DE/$86M-82.253.09-3.8%+0.53%
QCLSQ/C TECHNOLOGIES, INC.$32M-2.72+4.28%
VNRXVOLITIONRX LTD$12M-0.52+6.14%
CDIOCardio Diagnostics Holdings, Inc.$6M+2.53%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.